Logo image of AQB

AQUABOUNTY TECHNOLOGIES (AQB) Stock Fundamental Analysis

NASDAQ:AQB - US03842K3095 - Common Stock

0.908 USD
+0.14 (+18.86%)
Last: 8/27/2025, 10:29:20 PM
1.26 USD
+0.35 (+38.77%)
After Hours: 8/27/2025, 10:29:20 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AQB. AQB was compared to 547 industry peers in the Biotechnology industry. The financial health of AQB is average, but there are quite some concerns on its profitability. AQB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AQB has reported negative net income.
In the past year AQB has reported a negative cash flow from operations.
In the past 5 years AQB always reported negative net income.
AQB had a negative operating cash flow in each of the past 5 years.
AQB Yearly Net Income VS EBIT VS OCF VS FCFAQB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of AQB (-467.60%) is worse than 95.43% of its industry peers.
The Return On Equity of AQB (-811.04%) is worse than 80.44% of its industry peers.
Industry RankSector Rank
ROA -467.6%
ROE -811.04%
ROIC N/A
ROA(3y)-154.24%
ROA(5y)-97.11%
ROE(3y)-323.04%
ROE(5y)-198.77%
ROIC(3y)N/A
ROIC(5y)N/A
AQB Yearly ROA, ROE, ROICAQB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AQB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AQB Yearly Profit, Operating, Gross MarginsAQB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

4

2. Health

2.1 Basic Checks

AQB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AQB has more shares outstanding
AQB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for AQB is higher compared to a year ago.
AQB Yearly Shares OutstandingAQB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AQB Yearly Total Debt VS Total AssetsAQB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

AQB has an Altman-Z score of -17.95. This is a bad value and indicates that AQB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AQB (-17.95) is worse than 82.45% of its industry peers.
AQB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.95
ROIC/WACCN/A
WACC6.49%
AQB Yearly LT Debt VS Equity VS FCFAQB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 0.54 indicates that AQB may have some problems paying its short term obligations.
AQB has a Current ratio of 0.54. This is amonst the worse of the industry: AQB underperforms 92.50% of its industry peers.
A Quick Ratio of 0.54 indicates that AQB may have some problems paying its short term obligations.
AQB has a Quick ratio of 0.54. This is amonst the worse of the industry: AQB underperforms 91.77% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
AQB Yearly Current Assets VS Current LiabilitesAQB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for AQB have decreased strongly by -321.14% in the last year.
The Revenue for AQB has decreased by -98.13% in the past year. This is quite bad
EPS 1Y (TTM)-321.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.51%
Revenue 1Y (TTM)-98.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 12.23% on average over the next years. This is quite good.
Based on estimates for the next years, AQB will show a very strong growth in Revenue. The Revenue will grow by 74.02% on average per year.
EPS Next Y86.82%
EPS Next 2Y25.67%
EPS Next 3Y16.68%
EPS Next 5Y12.23%
Revenue Next Year43.65%
Revenue Next 2Y-25.67%
Revenue Next 3Y40.31%
Revenue Next 5Y74.02%

3.3 Evolution

AQB Yearly Revenue VS EstimatesAQB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M 8M
AQB Yearly EPS VS EstimatesAQB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AQB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AQB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQB Price Earnings VS Forward Price EarningsAQB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQB Per share dataAQB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as AQB's earnings are expected to grow with 16.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.67%
EPS Next 3Y16.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AQB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AQUABOUNTY TECHNOLOGIES

NASDAQ:AQB (8/27/2025, 10:29:20 PM)

After market: 1.26 +0.35 (+38.77%)

0.908

+0.14 (+18.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04
Earnings (Next)11-03 2025-11-03
Inst Owners7.9%
Inst Owner Change-6.04%
Ins Owners1.76%
Ins Owner Change0%
Market Cap3.52M
Analysts45
Price Target1.02 (12.33%)
Short Float %3.48%
Short Ratio1.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-39.89%
Min Revenue beat(4)-100%
Max Revenue beat(4)78.4%
Revenue beat(8)3
Avg Revenue beat(8)-14.91%
Revenue beat(12)3
Avg Revenue beat(12)-21.71%
Revenue beat(16)4
Avg Revenue beat(16)-21.62%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 73.7
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-35.61
EYN/A
EPS(NY)-7.35
Fwd EYN/A
FCF(TTM)-3.51
FCFYN/A
OCF(TTM)-3.06
OCFYN/A
SpS0.01
BVpS4.37
TBVpS4.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -467.6%
ROE -811.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-154.24%
ROA(5y)-97.11%
ROE(3y)-323.04%
ROE(5y)-198.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 543.01%
Cap/Sales 3681.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -17.95
F-Score3
WACC6.49%
ROIC/WACCN/A
Cap/Depr(3y)2285.55%
Cap/Depr(5y)1493.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-321.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.51%
EPS Next Y86.82%
EPS Next 2Y25.67%
EPS Next 3Y16.68%
EPS Next 5Y12.23%
Revenue 1Y (TTM)-98.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year43.65%
Revenue Next 2Y-25.67%
Revenue Next 3Y40.31%
Revenue Next 5Y74.02%
EBIT growth 1Y88.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.59%
EBIT Next 3Y32.51%
EBIT Next 5Y22.74%
FCF growth 1Y87.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.67%
OCF growth 3YN/A
OCF growth 5YN/A